Global Prostate Cancer PSMA-PET Imaging Agents Market Growth 2025-2031

The global Prostate Cancer PSMA-PET Imaging Agents market size is predicted to grow from US$ 1454 million in 2025 to US$ 3582 million in 2031; it is expected to grow at a CAGR of 16.2% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Prostate cancer PSMA-PET imaging agents are a type of radioactive molecular probes used for positron emission tomography (PET) imaging that can specifically bind to prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of prostate cancer cells. After injecting this imaging agent, PET scans can display the location and range of prostate cancer lesions in the body with high resolution. It is widely used in the early diagnosis, staging, recurrence monitoring and treatment plan formulation of prostate cancer, and is one of the key tools in current precision medicine for prostate cancer.

United States market for Prostate Cancer PSMA-PET Imaging Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Prostate Cancer PSMA-PET Imaging Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Prostate Cancer PSMA-PET Imaging Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Prostate Cancer PSMA-PET Imaging Agents players cover Telix, SOFIE, Novartis, Blue Earth Diagnostics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Prostate Cancer PSMA-PET Imaging Agents Industry Forecast” looks at past sales and reviews total world Prostate Cancer PSMA-PET Imaging Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Cancer PSMA-PET Imaging Agents sales for 2025 through 2031. With Prostate Cancer PSMA-PET Imaging Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer PSMA-PET Imaging Agents industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer PSMA-PET Imaging Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer PSMA-PET Imaging Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer PSMA-PET Imaging Agents market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer PSMA-PET Imaging Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer PSMA-PET Imaging Agents.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer PSMA-PET Imaging Agents market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Finished Injections
Lyophilized Kits

Segmentation by Application:
Diagnostics
Research and Drug Development

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Telix
SOFIE
Novartis
Blue Earth Diagnostics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prostate Cancer PSMA-PET Imaging Agents market?

What factors are driving Prostate Cancer PSMA-PET Imaging Agents market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prostate Cancer PSMA-PET Imaging Agents market opportunities vary by end market size?

How does Prostate Cancer PSMA-PET Imaging Agents break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.